JP2020510659A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510659A5 JP2020510659A5 JP2019546903A JP2019546903A JP2020510659A5 JP 2020510659 A5 JP2020510659 A5 JP 2020510659A5 JP 2019546903 A JP2019546903 A JP 2019546903A JP 2019546903 A JP2019546903 A JP 2019546903A JP 2020510659 A5 JP2020510659 A5 JP 2020510659A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- cd16a
- acid residues
- binding molecule
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17158566 | 2017-02-28 | ||
| EP17158566.4 | 2017-02-28 | ||
| EP17174407 | 2017-06-02 | ||
| EP17174407.1 | 2017-06-02 | ||
| PCT/EP2018/054989 WO2018158349A1 (en) | 2017-02-28 | 2018-02-28 | Tandem diabody for cd16a-directed nk-cell engagement |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510659A JP2020510659A (ja) | 2020-04-09 |
| JP2020510659A5 true JP2020510659A5 (enExample) | 2021-04-01 |
| JP7115758B2 JP7115758B2 (ja) | 2022-08-09 |
Family
ID=61569251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546903A Active JP7115758B2 (ja) | 2017-02-28 | 2018-02-28 | Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11180558B2 (enExample) |
| EP (1) | EP3589655B1 (enExample) |
| JP (1) | JP7115758B2 (enExample) |
| CN (1) | CN110382539B (enExample) |
| AU (1) | AU2018228719B2 (enExample) |
| CA (1) | CA3051062C (enExample) |
| DK (1) | DK3589655T3 (enExample) |
| WO (1) | WO2018158349A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020010728A (es) | 2018-04-13 | 2020-11-06 | Affimed Gmbh | Constructos de fusion de anticuerpos que se acoplan a celulas nk. |
| CA3187272A1 (en) * | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| WO2022161314A1 (zh) * | 2021-01-27 | 2022-08-04 | 信达生物制药(苏州)有限公司 | 针对cd16a的单域抗体及其用途 |
| US20240343811A1 (en) * | 2021-06-29 | 2024-10-17 | Shandong Simcere Biopharmacutical Co., Ltd. | Cd16 antibody and use thereof |
| AU2022381918A1 (en) * | 2021-11-03 | 2024-06-13 | Affimed Gmbh | Bispecific cd16a binders |
| TW202334221A (zh) * | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | 雙特異性cd16a結合劑 |
| CN114262382B (zh) * | 2021-12-20 | 2023-09-19 | 上海恩凯细胞技术有限公司 | 双特异性抗体及其应用 |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN115960234B (zh) * | 2022-10-27 | 2023-12-29 | 合肥天港免疫药物有限公司 | 抗cd16a的抗体及其应用 |
| WO2024131731A1 (zh) | 2022-12-19 | 2024-06-27 | 和铂医药(上海)有限责任公司 | "κ/λ"Fab-Fab串联多特异性结合蛋白及其制备和应用 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| ES2283368T3 (es) * | 2001-11-14 | 2007-11-01 | Affimed Therapeutics Ag | Anticuerpos biespecificos anti-cd19 y anti-cd16 y usos de los mismos. |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| MX2009013816A (es) * | 2007-06-21 | 2010-02-24 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos. |
| HRP20161194T1 (hr) | 2009-03-10 | 2016-11-04 | Biogen Ma Inc. | Anti-bcma protutijela |
| US20110206672A1 (en) * | 2010-02-25 | 2011-08-25 | Melvyn Little | Antigen-Binding Molecule And Uses Thereof |
| LT2361936T (lt) * | 2010-02-25 | 2016-09-12 | Affimed Gmbh | Antigeną rišanti molekulė ir jos panaudojimas |
| PH12013502421A1 (en) | 2011-05-27 | 2014-01-06 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| WO2013013700A1 (en) * | 2011-07-22 | 2013-01-31 | Affimed Therapeutics Ag | Multivalent antigen-binding fv molecule |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| PL2953972T3 (pl) | 2013-02-05 | 2021-03-08 | Engmab Sàrl | Metoda wyboru przeciwciał przeciwko bcma |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| WO2015018527A1 (en) * | 2013-08-07 | 2015-02-12 | Affimed Therapeutics Ag | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| HUE045866T2 (hu) * | 2015-05-04 | 2020-01-28 | Affimed Gmbh | CD30XCD16A antitest kombinálása anti-PD-1-antagonista antitesttel terápiához |
| CN105367660B (zh) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | 一种抗cd16a抗原和抗muc1抗原的双特异性抗体 |
-
2018
- 2018-02-28 JP JP2019546903A patent/JP7115758B2/ja active Active
- 2018-02-28 WO PCT/EP2018/054989 patent/WO2018158349A1/en not_active Ceased
- 2018-02-28 CN CN201880014655.0A patent/CN110382539B/zh active Active
- 2018-02-28 DK DK18708967.7T patent/DK3589655T3/da active
- 2018-02-28 AU AU2018228719A patent/AU2018228719B2/en active Active
- 2018-02-28 CA CA3051062A patent/CA3051062C/en active Active
- 2018-02-28 EP EP18708967.7A patent/EP3589655B1/en active Active
-
2019
- 2019-07-23 US US16/520,218 patent/US11180558B2/en active Active
-
2021
- 2021-10-26 US US17/510,738 patent/US12264198B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510659A5 (enExample) | ||
| JP2020517287A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| JP2022008382A5 (enExample) | ||
| JP2018518540A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP7663977B2 (ja) | 抗ｐｄ―ｌ１抗体およびその用途 | |
| JP2020510422A5 (enExample) | ||
| JP2013515508A5 (enExample) | ||
| FI3328893T3 (fi) | Mesoteliinia ja cd3:a sitovia bispesifisiä vasta-ainekonstrukteja | |
| JP2018523493A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2019054802A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| JP2020506898A5 (enExample) | ||
| TW201643193A (zh) | 一種抗ｐｄ－１的單克隆抗體及其獲得方法 | |
| JP2016138129A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2017520575A5 (enExample) | ||
| JP2016501839A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| JP2014158485A5 (enExample) | ||
| JP2005518789A5 (enExample) |